October 26, 2020October 27, 2020

Adding Ibrance to Hormone Therapy Fails to Prolong Time Before Cancer Recurs, Trial Shows

News

Adding Ibrance (palbociclib) to standard endocrine therapy failed to prolong the time women with early hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative breast cancer lived without having their disease ... Read more

June 15, 2020June 15, 2020

Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says

News

An independent data monitoring committee (DMC) has deemed it unlikely that a combination of endocrine therapy and Pfizer’s Ibrance (palbociclib) will show benefits over standard therapy at delaying or preventing ... Read more